R&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
PLoS One. 2024 Jul 25;19(7):e0305911. doi: 10.1371/journal.pone.0305911. eCollection 2024.
Chronic obstructive pulmonary disease (COPD), an inflammatory lung disease, causes approximately 3 million deaths each year; however, its pathological mechanisms are not fully understood. In this study, we examined whether HX110B, a mixture of Taraxacum officinale, Dioscorea batatas, and Schizonepeta tenuifolia extracts, could suppress porcine pancreatic elastase (PPE)-induced emphysema in mice and its mechanism of action. The therapeutic efficacy of HX110B was tested using a PPE-induced emphysema mouse model and human bronchial epithelial cell line BEAS-2B. In vivo data showed that the alveolar wall and air space expansion damaged by PPE were improved by HX110B administration. HX110B also effectively suppresses the expression levels of pro-inflammatory mediators including IL-6, IL-1β, MIP-2, and iNOS, while stimulating the expression of lung protective factors such as IL-10, CC16, SP-D, and sRAGE. Moreover, HX110B improved the impaired OXPHOS subunit gene expression. In vitro analysis revealed that HX110B exerted its effects by activating the PPAR-RXR signaling pathways. Overall, our data demonstrated that HX110B could be a promising therapeutic option for COPD treatment.
慢性阻塞性肺疾病(COPD)是一种炎症性肺部疾病,每年导致约 300 万人死亡;然而,其病理机制尚未完全阐明。在这项研究中,我们研究了蒲公英、山药和荆芥混合物 HX110B 是否可以抑制猪胰弹性蛋白酶(PPE)诱导的小鼠肺气肿及其作用机制。使用 PPE 诱导的肺气肿小鼠模型和人支气管上皮细胞系 BEAS-2B 测试了 HX110B 的治疗功效。体内数据表明,HX110B 给药可改善由 PPE 引起的肺泡壁和气腔扩张损伤。HX110B 还能有效抑制包括 IL-6、IL-1β、MIP-2 和 iNOS 在内的促炎介质的表达水平,同时刺激肺保护因子如 IL-10、CC16、SP-D 和 sRAGE 的表达。此外,HX110B 改善了受损的 OXPHOS 亚基基因表达。体外分析表明,HX110B 通过激活 PPAR-RXR 信号通路发挥作用。总的来说,我们的数据表明 HX110B 可能是治疗 COPD 的一种有前途的治疗选择。